Can I take a cheaper version of Rinvoq?
While Rinvoq (upadacitinib) is a brand-name medication, there isn't a generic version available yet [1]. Upadacitinib's patent protection is still in effect, and the manufacturer, AbbVie, has control over the market. However, biosimilars are being developed and tested to replicate the effects of Rinvoq.
What's the status of biosimilars for Rinvoq?
Several companies, including Amgen and Samsung Bioepis, are working on biosimilars for upadacitinib, but none have been approved by the FDA [2]. Biosimilars must meet rigorous standards and demonstrate equivalence to the original medicine in terms of safety and efficacy. While approval times can vary, the FDA has been accelerating the approval process for biosimilars in recent years.
Why are biosimilars important for patients?
Biosimilars can offer patients alternative treatment options at lower costs, improving access to essential therapies [3]. The introduction of biosimilars can also increase competition in the market, driving innovation and pushing companies to improve their products.
When can I expect a generic or biosimilar version of Rinvoq?
The availability of a generic or biosimilar version of Rinvoq depends on the patent landscape, regulatory approval timelines, and market entry strategies of the companies involved. While it's difficult to predict an exact timeline, patients can expect increased competition and potentially more affordable options in the coming years.
References:
[1] DrugPatentWatch.com: Upadacitinib patent information https://www.drugpatentwatch.com/patent/US11312992
[2] FDA: Biosimilars https://www.fda.gov/drugs/news-events-human-drugs/biosimilars
[3] European Medicines Agency: Biosimilars https://www.ema.europa.eu/en/medicines/biosimilars